This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2024
AMA 2024
ASCO 2024
AUA 2024
APCCC 2024
All Conferences
View All
PCF
UroToday Home
Newsletter Archive
GU Onc Daily
UroAlert - GU Oncology Daily
June 24, 2024
Videos
Peer-to-Peer Clinical Conversations
MMAI Model Risk Stratification for NCCN Guidelines for Low, Intermediate, and High-Risk Prostate Cancer - Neal Shore, Daniel Spratt, & Alicia Morgans
Neal Shore
Zach Klaassen hosts a multidisciplinary roundtable discussing the NCCN Prostate Cancer Guidelines with a focus on the ArteraAI prostate test.
View
The Triangle Offense: Harnessing NK Cells, T-Cells, and Memory Cells in Bladder Cancer - Patrick Soon-Shiong
Patrick Soon-Shiong
Ashish Kamat interviews Patrick Soon-Shiong about the approval of Anktiva for bladder cancer treatment.
View
Beyond the Abstracts
Magnetic Resonance Imaging-Based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study - Beyond the Abstract
Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis) - Beyond the Abstract
Conference Coverage
ASCO 2024: Veterans Affairs Seamless Phase II/III Randomized Trial of Standard Systemic Therapy with or Without PET-Directed Local Therapy for Oligometastatic Prostate Cancer (VA STARPORT)
ASCO 2024: Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches
ASCO 2024: Quantitative Circulating Tumor DNA (ctDNA) Assessment in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab or Platinum-Based Chemotherapy from the Phase 3 KEYNOTE-361 Trial
Articles
Editor Selected Abstracts and Commentaries
Bladder Cancer
The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Establishing an Intravesical Doublet Chemotherapy Clinic for Nonmuscle-Invasive Bladder Cancer Patients.
Voided Urine Cytology Is a Useful Tool Predicting Non-Muscle-Invasive Bladder Cancer Risk Before Surgery - Beyond the Abstract
Penile & Urethral Cancers
Therapeutic Targets in Advanced Penile Cancer: From Bench to Bedside.
Comparative outcomes of partial versus total penectomy for penile carcinoma: A retrospective cohort study on demographics and postoperative complications.
Renal Cancer
Integrated mendelian randomization analyses highlight AFF3 as a novel eQTL-mediated susceptibility gene in renal cancer and its potential mechanisms.
The impact of the location, incidence and distribution of lung metastases in primary colorectal and renal cell cancer patients on prognosis: a retrospective observational study.
Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis.
Patient's Self-Reported Quality of Life as a Prognostic Factor in Metastatic Renal Cell Carcinoma Initially Treated with TKI: Nomogram Proposal - Beyond the Abstract
Prostate Cancer
Association of Tumor Genetics with Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies.
Reasons for Discordance between 68Ga-PSMA-PET and Magnetic Resonance Imaging in Men with Metastatic Prostate Cancer.
Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform.
Prostate Cancer Risk Stratification by Digital Histopathology and Deep Learning.
Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Mixed Methods Approach to Identify Effective Interventions.
Activity of Lutetium-177 Prostate-Specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study - Beyond the Abstract
CONNECT WITH US
Questions or Comments? Email us at
editors@urotoday.com
Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523
You are receiving this email because you have chosen to receive emails from UroToday.
Add us to your address book
View this email as a web page
Forward to a colleague
Manage your subscriptions
Unsubscribe
Copyright ©2024 Digital Science Press, LLC
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free